Sort by
Items per page

Send to

Choose Destination

Best matches for ATM and Brain:

Involvement of Atm and Trp53 in neural cell loss due to Terf2 inactivation during mouse brain development. Kim J et al. Histochem Cell Biol. (2017)

ATM in breast and brain tumors: a comprehensive review. Estiar MA et al. Cancer Biol Med. (2018)

DNA-PKcs, ATM, and ATR Interplay Maintains Genome Integrity during Neurogenesis. Enriquez-Rios V et al. J Neurosci. (2017)

Search results

Items: 1 to 20 of 1013


Calling RNF168 to action.

Nowsheen S, Lou Z.

Cell Stress. 2018 May 10;2(5):113-114. doi: 10.15698/cst2018.05.135.


The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer.

Chen D, Chu T, Chang Q, Zhang Y, Xiong L, Qiao R, Teng J, Han B, Zhong R.

Ann Transl Med. 2019 May;7(9):195. doi: 10.21037/atm.2019.04.06.


Pharmacogenetics of Metformin for Medication-Induced Weight Gain in Autism Spectrum Disorder.

Garfunkel D, Anagnostou EA, Aman MG, Handen BL, Sanders KB, Macklin EA, Chan J, Veenstra-VanderWeele J.

J Child Adolesc Psychopharmacol. 2019 Jun 12. doi: 10.1089/cap.2018.0171. [Epub ahead of print]


Difficulties in diagnosis and treatment of Wilson disease-a case series of five patients.

Członkowska A, Dzieżyc-Jaworska K, Kłysz B, Barbara RO, Litwin T.

Ann Transl Med. 2019 Apr;7(Suppl 2):S73. doi: 10.21037/atm.2019.02.37.


Determination of copper poisoning in Wilson's disease using laser ablation inductively coupled plasma mass spectrometry.

Weiskirchen S, Kim P, Weiskirchen R.

Ann Transl Med. 2019 Apr;7(Suppl 2):S72. doi: 10.21037/atm.2018.10.67. Review.


Wilson disease-treatment perspectives.

Litwin T, Dzieżyc K, Członkowska A.

Ann Transl Med. 2019 Apr;7(Suppl 2):S68. doi: 10.21037/atm.2018.12.09. Review.


Neurologic impairment in Wilson disease.

Dusek P, Litwin T, Członkowska A.

Ann Transl Med. 2019 Apr;7(Suppl 2):S64. doi: 10.21037/atm.2019.02.43. Review.


Clinical manifestations of Wilson disease in organs other than the liver and brain.

Dzieżyc-Jaworska K, Litwin T, Członkowska A.

Ann Transl Med. 2019 Apr;7(Suppl 2):S62. doi: 10.21037/atm.2019.03.30. Review.


Genetics and epigenetic factors of Wilson disease.

Medici V, LaSalle JM.

Ann Transl Med. 2019 Apr;7(Suppl 2):S58. doi: 10.21037/atm.2019.01.67. Review.


Nuclear Phospho-SOD1 Protects DNA from Oxidative Stress Damage in Amyotrophic Lateral Sclerosis.

Bordoni M, Pansarasa O, Dell'Orco M, Crippa V, Gagliardi S, Sproviero D, Bernuzzi S, Diamanti L, Ceroni M, Tedeschi G, Poletti A, Cereda C.

J Clin Med. 2019 May 22;8(5). pii: E729. doi: 10.3390/jcm8050729.


Cardiac Nuclear High-Mobility Group Box 1 Ameliorates Pathological Cardiac Hypertrophy by Inhibiting DNA Damage Response.

Takahashi T, Shishido T, Kinoshita D, Watanabe K, Toshima T, Sugai T, Narumi T, Otaki Y, Tamura H, Nishiyama S, Arimoto T, Takahashi H, Miyamoto T, Watanabe T, Woo CH, Abe JI, Takeishi Y, Kubota I, Watanabe M.

JACC Basic Transl Sci. 2019 Apr 29;4(2):234-247. doi: 10.1016/j.jacbts.2018.11.011. eCollection 2019 Apr.


Clinical features and prognosis of patients with Guillain-Barré and acute transverse myelitis overlap syndrome.

Guo F, Zhang YB.

Clin Neurol Neurosurg. 2019 Jun;181:127-132. doi: 10.1016/j.clineuro.2019.04.014. Epub 2019 Apr 15.


Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.

Zhou M, Sareddy GR, Li M, Liu J, Luo Y, Venkata PP, Viswanadhapalli S, Tekmal RR, Brenner A, Vadlamudi RK.

Sci Rep. 2019 Apr 16;9(1):6124. doi: 10.1038/s41598-019-42313-8.


Decrease of Nibrin expression in chronic hypoxia is associated with hypoxia-induced chemoresistance in some brain tumour cells.

Cowman S, Fan YN, Pizer B, Sée V.

BMC Cancer. 2019 Apr 3;19(1):300. doi: 10.1186/s12885-019-5476-9.


Rare paraneoplastic erythroderma associated with ectopic neuron-specific enolase deposition in basal cells.

Wang L, Guo T, Zhang H, Li W, Zhu Y, Guo H, Yang F, Guo Y, Zhang Z, Han Y, Zhong D, Li X, Huang L.

Ann Transl Med. 2019 Feb;7(3):51. doi: 10.21037/atm.2018.12.04.


Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.

Toledo-Sherman L, Breccia P, Cachope R, Bate JR, Angulo-Herrera I, Wishart G, Matthews KL, Martin SL, Cox HC, McAllister G, Penrose SD, Vater H, Esmieu W, Van de Poël A, Van de Bospoort R, Strijbosch A, Lamers M, Leonard P, Jarvis RE, Blackaby W, Barnes K, Eznarriaga M, Dowler S, Smith GD, Fischer DF, Lazari O, Yates D, Rose M, Jang SW, Muñoz-Sanjuan I, Dominguez C.

J Med Chem. 2019 Mar 28;62(6):2988-3008. doi: 10.1021/acs.jmedchem.8b01819. Epub 2019 Mar 19.


Genotype-phenotype correlations in ataxia telangiectasia patients with ATM c.3576G>A and c.8147T>C mutations.

van Os NJH, Chessa L, Weemaes CMR, van Deuren M, Fiévet A, van Gaalen J, Mahlaoui N, Roeleveld N, Schrader C, Schindler D, Taylor AMR, Van de Warrenburg BPC, Dörk T, Willemsen MAAP.

J Med Genet. 2019 May;56(5):308-316. doi: 10.1136/jmedgenet-2018-105635. Epub 2019 Feb 28.


Clinico-pathological correlation in case of BRAT1 mutation.

Szymańska K, Laure-Kamionowska M, Szczałuba K, Koppolu A, Furmanek M, Kuśmierska K, Boniel S, Płoski R, Rydzanicz M.

Folia Neuropathol. 2018;56(4):362-371. doi: 10.5114/fn.2018.80870.


Sense and sensibility: ATM oxygen stress signaling manages brain cell energetics.

Schlacher K.

J Cell Biol. 2019 Mar 4;218(3):732-734. doi: 10.1083/jcb.201901050. Epub 2019 Feb 19.


Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.

Murphy C, Muscat A, Ashley D, Mukaro V, West L, Liao Y, Chisanga D, Shi W, Collins I, Baron-Hay S, Patil S, Lindeman G, Khasraw M.

PLoS One. 2019 Feb 14;14(2):e0210891. doi: 10.1371/journal.pone.0210891. eCollection 2019.

Supplemental Content

Loading ...
Support Center